galsulfase
| Brand name | Naglazyme |
|---|---|
| Active ingredient | galsulfase |
| Strength | 5MG/5ML (1MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | May 2005 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.